PMVP
Pmv Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PMVP
Pmv Pharmaceuticals, Inc.
A precision oncology company that develops p53-targeted small molecule drugs for the treatment of cancer
One Research Way, Princeton, NJ 08540
--
Pmv Pharmaceuticals, Inc., was incorporated in Delaware in March 2013. The company is a precision oncology company dedicated to the discovery and development of small molecule, tumor-independent therapies for p53 mutations. P53 is a well-defined tumor suppressor protein known as the "guardian of the genome," while normal or wild-type p53 has the ability to eliminate cancer cells.
Company Financials
EPS
PMVP has released its 2025 Q3 earnings. EPS was reported at -0.4, versus the expected -0.4, meeting expectations. The chart below visualizes how PMVP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
